FAP and neoplasm: Thus, targeting FAP+ stromal cells with CAR T-cells can greatly broaden the application of this therapy, and we hypothesize that using CAR T-cells to selectively eliminate FAP+ cells may improve patient survival, given the tumor-promoting effects of FAP+ CAFs.